Patif Max | Olopatadine Hydrochloride Ophthalmic Solution IP 0.7% w/v

Mechanism of Action:

Olopatadine is a potent selective antiallergic/antihistaminic agent that exerts its effects through multiple distinct mechanisms of action. It antagonises histamine (the primary mediator of allergic response in humans) and prevents histamine induced inflammatory cytokine production by human conjunctival epithelial cells. Data from in vitro studies suggest that it may act on human conjunctival mast cells to inhibit the release of pro-inflammatory mediators. In patients with patent nasolacrimal ducts, topical ocular administration of Patif Max was suggested to reduce the nasal signs and symptoms that frequently accompany seasonal allergic conjunctivitis. It does not produce a clinically significant change in pupil diameter.

Indication:

Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.

Warning:

Olopatadine is an antiallergic/antihistaminic agent and, although administered topically, is absorbed systemically. If signs of serious reactions or hypersensitivity occur, discontinue the use of this treatment.

Olopatadine contains cetrimide which may cause eye irritation.

Precautions:

Cetrimide also been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Close monitoring ir required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.

Cetrimide is known to discolour soft contact lenses. Avoid contact with soft contact lenses.

Patients should be instructed to remove contact lenses prior to administration of the eye drop and wait at least 15 minutes after instillation before re-inserting contact lenses.

Dosage: As directed by the physician.

Presentation: Patif Max eye drops is available in 5ml pack

Storage: Store protected from light and moisture, at a temperature between 4° to 25°.

Keep the medicine out of reach of children

FOR OPHTHALMIC USE ONLY

NOT FOR INJECTION